CDT enters evaluation agreement with Manoira for AZD1656 and AZD5904
CDT Equity Inc. entered an October 22, 2026 evaluation agreement with Manoira Corporation under which Manoira will evaluate CDT's clinical-stage assets AZD1656, including certain cocrystal derivatives, and AZD5904 in combination with Manoira's planned animal health products. CDT settled the US$195,000 evaluation fee with 1,347,616 common shares at $0.1447 per share, and if the results show an improved product offering the parties intend to negotiate a development, licensing and commercialization agreement for 12...
Read source-backed brief